SCHEMBL718937

SCHEMBL718937

ClC(c1nn(C2CCCCC2)c2ccccc12)C1CCCCC1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR2 P34972 3/20 0.40
CNR1 P21554 2/20 0.40
PDE4A P27815 3/20 0.38
PDE4B Q07343 3/20 0.38
PDE4C Q08493 3/20 0.38
PDE4D Q08499 3/20 0.38
PDE3B Q13370 1/20 0.38
PDE3A Q14432 1/20 0.38
ESR1 P03372 3/20 0.36
IDO1 P14902 2/20 0.36
HPGD P15428 1/20 0.35
TP53 P04637 1/20 0.34
HTR3E A5X5Y0 1/20 0.34
SLC22A2 O15244 1/20 0.34
HTR3B O95264 1/20 0.34
CHRNB2 P17787 1/20 0.34
CHRNA3 P32297 1/20 0.34
CHRNA4 P43681 1/20 0.34
HTR3A P46098 1/20 0.34
KCNH2 Q12809 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL717278 0.83 IDO1 (0.41) CNR2CNR1PDE4APDE4BPDE4C
SCHEMBL720196 0.82 HTR3A (0.42) IDO1HTR3ESLC22A2HTR3BCHRNB2
SCHEMBL721320 0.80 L3MBTL1 (0.40) CNR2CNR1IDO1HPGDTP53
SCHEMBL24117840 0.73 ALDH1A1 (0.36) PDE4APDE4BPDE4CPDE4DPDE3B
SCHEMBL17018057 0.73 PDE4A (0.42) CNR2CNR1PDE4APDE4BPDE4C
SCHEMBL5141079 0.71 PDE4A (0.40) CNR2CNR1PDE4APDE4BPDE4C
SCHEMBL8718851 0.70 HTR3A (0.44) CNR2CNR1PDE4APDE4BPDE4C
SCHEMBL716808 0.70 PDE4A (0.43) CNR2CNR1PDE4APDE4BPDE4C
SCHEMBL27834153 0.70 PDE4A (0.43) CNR2CNR1PDE4APDE4BPDE4C
SCHEMBL27540455 0.70 PDE4A (0.45) CNR2CNR1PDE4APDE4BPDE4C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-102015641-B Heterocyclic compound TAKEDA PHARMACEUTICAL 2014-01-01 CN disclosed
US-8436043-B2 Heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-05-07 US disclosed
US-20120270865-A2 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-10-25 US disclosed
US-20120053173-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-03-01 US disclosed
CN-102015641-A Heterocyclic compound TAKEDA PHARMACEUTICAL 2011-04-13 CN disclosed
EP-2251326-A1 HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2010-11-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120053173-A1 HETEROCYCLIC COMPOUND SLC5A2, SLC5A1, IAPP CNR2 1387/4885CNR1 1378/4885PDE4A 1131/4885
US-20120270865-A2 HETEROCYCLIC COMPOUND SLC5A2, SLC5A1, IAPP CNR2 1387/4885CNR1 1378/4885PDE4A 1131/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.